Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 13/20 | 1.00 |
| ▸ | MAOB | P27338 | 13/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | CASP3 | P42574 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.64 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.64 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.64 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1902132 | 0.99 | MAOA (0.97) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL10034861 | 0.93 | MAOA (0.86) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL2242637 | 0.87 | MAOA (0.77) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL1903721 | 0.86 | MAOA (1.00) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL729793 | 0.85 | MAOA (1.00) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL1903836 | 0.84 | MAOA (1.00) | MAOAMAOBNPC1CASP3RAB9A | |
| Hydrochloric Acid SCHEMBL1829967 | 0.84 | MAOA (0.98) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL727711 | 0.83 | MAOA (1.00) | MAOAMAOBNPC1CASP3RAB9A | |
| Hydrochloric Acid SCHEMBL1900894 | 0.83 | MAOA (0.98) | MAOAMAOBNPC1CASP3RAB9A | |
| SCHEMBL12676057 | 0.83 | MAOA (0.70) | MAOAMAOBNPC1CASP3RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | claimed |
| EP-2315588-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM SPA (IT) | 2012-12-19 | — | — | EP | claimed |
| JP-2011524383-A | — | — | 2011-09-01 | — | — | JP | claimed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | claimed |
| EP-2315588-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | Rottapharm S.p.A. (IT) | 2011-05-04 | — | — | EP | claimed |
| WO-2009152868-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2009-12-23 | — | — | WO | claimed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| US-8633208-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new MAO inhibitors and imidazoline receptor ligands | ROTTAPHARM S.P.A (IT) | 2014-01-21 | — | — | US | disclosed |
| EP-2315588-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM SPA (IT) | 2012-12-19 | — | — | EP | disclosed |
| EP-2066653-B1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM SPA (IT) | 2012-09-12 | — | — | EP | disclosed |
| US-8193353-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A (IT) | 2012-06-05 | — | — | US | disclosed |
| US-8193353-B2 | 6-1H-imidazo-quinazoline and quinolines derivatives, new potent analgesics and anti-inflammatory agents | ROTTAPHARM S.P.A (IT) | 2012-06-05 | — | — | US | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2011-05-19 | — | — | US | disclosed |
| WO-2009152868-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | ROTTAPHARM S.P.A. (IT) | 2009-12-23 | — | — | WO | disclosed |
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-10-22 | — | — | US | disclosed |
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-10-22 | — | — | US | disclosed |
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2009-10-22 | — | — | US | disclosed |
| WO-2008014822-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | ROTTAPHARM S.P.A. (IT) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264451-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW POTENT ANALGESICS AND ANTI-INFLAMMATORY AGENTS | IL1A, IL6, IL1B | MAOA 3094/4885MAOB 3506/4885NPC1 3241/4885 |
| US-20110118289-A1 | 6-1H-IMIDAZO-QUINAZOLINE AND QUINOLINES DERIVATIVES, NEW MAO INHIBITORS AND IMIDAZOLINE RECEPTOR LIGANDS | OPRM1, OPRD1, HTR3C | MAOA 8/4885MAOB 10/4885NPC1 4082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.